22nd Century Debt to Equity Ratio 2011-2023 | XXII
Current and historical debt to equity ratio values for 22nd Century (XXII) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. 22nd Century debt/equity for the three months ending December 31, 2023 was 0.01.
| 22nd Century Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2023-12-31 |
$0.04B |
$-0.01B |
-4.27 |
| 2023-09-30 |
$0.05B |
$0.01B |
3.65 |
| 2023-06-30 |
$0.05B |
$0.07B |
0.72 |
| 2023-03-31 |
$0.04B |
$0.08B |
0.53 |
| 2022-12-31 |
$0.02B |
$0.10B |
0.20 |
| 2022-09-30 |
$0.02B |
$0.12B |
0.17 |
| 2022-06-30 |
$0.02B |
$0.10B |
0.20 |
| 2022-03-31 |
$0.01B |
$0.06B |
0.15 |
| 2021-12-31 |
$0.01B |
$0.07B |
0.15 |
| 2021-09-30 |
$0.01B |
$0.08B |
0.09 |
| 2021-06-30 |
$0.01B |
$0.09B |
0.11 |
| 2021-03-31 |
$0.01B |
$0.05B |
0.14 |
| 2020-12-31 |
$0.01B |
$0.04B |
0.17 |
| 2020-09-30 |
$0.01B |
$0.05B |
0.15 |
| 2020-06-30 |
$0.01B |
$0.05B |
0.14 |
| 2020-03-31 |
$0.01B |
$0.06B |
0.11 |
| 2019-12-31 |
$0.01B |
$0.06B |
0.11 |
| 2019-09-30 |
$0.01B |
$0.06B |
0.12 |
| 2019-06-30 |
$0.01B |
$0.06B |
0.13 |
| 2019-03-31 |
$0.01B |
$0.07B |
0.11 |
| 2018-12-31 |
$0.01B |
$0.07B |
0.08 |
| 2018-09-30 |
$0.01B |
$0.08B |
0.09 |
| 2018-06-30 |
$0.01B |
$0.07B |
0.08 |
| 2018-03-31 |
$0.01B |
$0.08B |
0.07 |
| 2017-12-31 |
$0.00B |
$0.08B |
0.06 |
| 2017-09-30 |
$0.00B |
$0.03B |
0.13 |
| 2017-06-30 |
$0.00B |
$0.03B |
0.17 |
| 2017-03-31 |
$0.00B |
$0.02B |
0.16 |
| 2016-12-31 |
$0.00B |
$0.02B |
0.14 |
| 2016-09-30 |
$0.00B |
$0.02B |
0.21 |
| 2016-06-30 |
$0.00B |
$0.01B |
0.27 |
| 2016-03-31 |
$0.00B |
$0.02B |
0.24 |
| 2015-12-31 |
$0.01B |
$0.01B |
0.57 |
| 2015-09-30 |
$0.01B |
$0.01B |
0.48 |
| 2015-06-30 |
$0.01B |
$0.02B |
0.41 |
| 2015-03-31 |
$0.01B |
$0.01B |
0.54 |
| 2014-12-31 |
$0.01B |
$0.02B |
0.44 |
| 2014-09-30 |
$0.01B |
$0.02B |
0.33 |
| 2014-06-30 |
$0.00B |
$0.01B |
0.23 |
| 2014-03-31 |
$0.00B |
$0.01B |
0.17 |
| 2013-12-31 |
$0.01B |
$0.01B |
0.63 |
| 2013-09-30 |
$0.02B |
$-0.02B |
-1.23 |
| 2013-06-30 |
$0.01B |
$-0.01B |
-1.44 |
| 2013-03-31 |
$0.01B |
$-0.01B |
-1.38 |
| 2012-12-31 |
$0.01B |
$-0.01B |
-1.43 |
| 2012-09-30 |
$0.01B |
$-0.00B |
-2.12 |
| 2012-06-30 |
$0.01B |
$-0.00B |
-2.34 |
| 2012-03-31 |
$0.01B |
$-0.00B |
-1.79 |
| 2011-12-31 |
$0.00B |
$-0.00B |
-2.97 |
| 2011-09-30 |
$0.01B |
$-0.00B |
-1.76 |
| 2011-06-30 |
$0.01B |
$-0.00B |
-2.02 |
| 2011-03-31 |
$0.01B |
$-0.00B |
-2.92 |
| 2010-12-31 |
$0.01B |
$-0.00B |
-2.35 |
| Sector |
Industry |
Market Cap |
Revenue |
| Consumer Staples |
Tobacco Products |
$0.006B |
$0.032B |
|
22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York.
|
